Performance status of patients is the major prognostic factor at all stages of pancreatic cancer

Tas F., Sen F., Odabas H., Kilic L., Keskin S., Yildiz I.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.18, no.5, pp.839-846, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 5
  • Publication Date: 2013
  • Doi Number: 10.1007/s10147-012-0474-9
  • Journal Name: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.839-846
  • Keywords: Pancreatic cancer, Performance status, Prognosis, Survival, PHASE-III TRIAL, GEMCITABINE, SURVIVAL, ADENOCARCINOMA, RESECTION, CHEMOTHERAPY, CA-19-9, METASTASIS, CARCINOMA
  • Istanbul University Affiliated: Yes

Abstract

The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer.